Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Medicover

227.00 SEK

-1.73 %

Less than 1K followers

MCOV B

NASDAQ Stockholm

Health Care Providers

Health Care

-1.73 %
-6.78 %
-15.30 %
-5.22 %
+18.23 %
+24.73 %
+64.02 %
+63.07 %
+246.56 %

Medicover operates in the healthcare industry. The company is an international healthcare and diagnostics company and focuses on providing medical services and laboratory analyses. The company's services are aimed at individuals and companies that need fast and accessible care. Medicover was founded in 1994 and is headquartered in Stockholm, Sweden.

Read more
Market cap
34.85B SEK
Turnover
10.53M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2.
2026

Annual report '25

29.4.
2026

General meeting '26

29.4.
2026

Interim report Q1'26

ShowingAll content types
Third party research

Medicover: Execution remains solid - ABG

* Operational leverage supports beat on adj. EBITDA* Adj. EBITDA revised by +1-0% for '25e-'27e* Unchanged outlook and fair value range of SEK 220-300Continues to show strengthQ3 proved marginally weaker than expected on sales, but operational leverage...

Medicover

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

Medicover: Margins expand, despite slower growth - ABG

* +5%/+3% adj. EBITDA vs ABGSCe/Infront cons in Q3* Cons estimates likely up 1-2% on adj. EBITDA '25e* Somewhat lower sales but profitability continues to improveQ3 resultsMedicover reported a solid Q3 with a miss on sales but a beat on adj. EBITDA (...

Medicover
Third party research

Medicover: Strong and stable core, minor adjustments - ABG

* Q3'25 numbers due on 5 November at 07:45 CET* Adj. EBITDA down 1% for '25e-'27e* Fair value range unchanged at SEK 220-300 Q3'25 expectations For Q3, we expect Medicover to continue to deliver strong growth in its core regions and drive margin expansion...

Medicover
Third party research

Medicover: A charmingly aggressive CEO - ABG

* Scale and presence underpin growth and margin expansion* Sharper execution on cross-segment synergies* Trading at ~13x '25e EV/EBITDAPresence mattersWe hosted Medicover’s CEO John Stubbington and CFO Anand Patel for lunch earlier today. The discussion...

Medicover
Third party research

Medicover: Still shining bright - ABG

Q2 results Medicover reported an adj. EBITDA beat in Q2 (+7%/+7% vs. ABGSCe/cons), with better than expected margins in both segments. Q2 sales was EUR 597m (0% vs ABGSCe, 0% vs cons). Total organic sales growth in Q2 was +14% (ABGSCe +16%).Adj. EBITDA...

Medicover
Third party research

Medicover: Full steam ahead - ABG

Q2'25 numbers due on 24 July at 07:45 CET Adj. EBITDA flat, EBIT up 2% for '25e-'27e Unchanged story, fair value range up to SEK 190-270 (180-260) Q2'25 expectations Ahead of Q2, Medicover’s strong growth trajectory and expanding margins are expected...

Medicover
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.